Production of biologic active ingredients at the site is scheduled to start in 2026. Part of the Limerick site's production capacity has been earmarked for donanemab, which was approved by the US ...
The United Kingdom medicines authority approved the Alzheimer’s disease drug Kisunla (donanemab) last week for certain patients. This follows the Unites States Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback